Meditemp
Varicoceles Infertility Treatment
Health Tech & Life Sciences
Acquired (Inactive) by Generex Biotechnology Corporation on Oct 2015 - closed due to acquisition
Company Overview
Snapshot
Founded in January 2007, Meditemp operates with 1–10 employees. The company was acquired by Generex Biotechnology Corporation in October 2015.
Business overview
Meditemp is a Health Tech & Life Sciences company focused on developing medical devices for male infertility. The company's core product, Varicure, is a compact and portable cooling device designed to improve sperm quality in men with varicoceles by facilitating localized testicular cooling. This non-invasive treatment aims to restore male fertility, offering a conservative and economic first-line therapy option. Meditemp primarily serves the healthcare industry, specifically targeting providers within the medical treatment and therapeutics sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Meditemp's primary product?
- Meditemp's primary product is Varicure, a compact and portable cooling device designed to improve sperm quality in men who are infertile due to varicoceles.
- When was Meditemp founded?
- Meditemp was founded in January 2007.
- What is the primary sector Meditemp operates in?
- Meditemp operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.
- What is the status of Meditemp?
- Meditemp was acquired by Generex Biotechnology Corporation in October 2015 and is currently inactive.
- What problem does Meditemp's technology address?
- Meditemp's technology addresses male infertility caused by varicoceles, aiming to restore fertility by improving semen quality through localized testicular cooling.